Current Report Filing (8-k)
August 11 2022 - 04:18PM
Edgar (US Regulatory)
0001599298FALSE00015992982022-08-112022-08-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of Earliest Event Reported):
August 11, 2022
|
|
|
|
|
|
|
|
|
|
Summit Therapeutics Inc. |
|
(Exact Name of Registrant as Specified in Its Charter) |
|
|
|
|
|
Delaware |
001-36866 |
37-1979717 |
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
|
|
|
2882 Sand Hill Road, Suite 106, Menlo Park, CA
|
94025 |
|
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
617-514-7149
|
|
|
|
Not applicable |
|
(Former Name or Former Address, If Changed Since Last
Report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange on Which Registered |
|
Common stock, $0.01 par value per share |
SMMT |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
|
|
|
|
|
|
|
Item 2.02 |
Results of Operations and Financial Condition. |
On August 11, 2022, Summit Therapeutics Inc. (the "Company")
announced its financial results and operational progress for the
second quarter ended June 30, 2022. A copy of the press release is
being furnished as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
The information in this Item 2.02 of this Current Report on Form
8-K and Exhibit 99.1 attached hereto is intended to be furnished
and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such
filing.
|
|
|
|
|
|
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
|
|
|
|
Exhibit Number
|
Description |
|
|
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL
document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
SUMMIT THERAPEUTICS INC. |
|
|
|
|
|
|
|
Date: August 11, 2022 |
By: |
/s/ Ankur Dhingra |
|
|
|
Chief Financial Officer |
|
|
|
(Principal Financial Officer) |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Feb 2023 to Mar 2023
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2022 to Mar 2023
